OsteoMD has exclusive distribution rights in Europe, Americas and Africa for Crespine Gel. Crespine Gel is a single injection, hyaluronic acid-based treatment for osteoarthritis. It is CE approved and classified as a medical device rather than a pharmaceutical, making it easier to introduce into new countries. Developed and produced in Germany, Crespine Gel has a unique formulation that makes it superior to all its current competitors.
Ignitas is assisting OsteoMD with financing, visibility strategies, e-marketing, branding, visual identity and corporate communications.
Similar Projects
Donec sed odio dui. Nulla vitae elit librero, a pharetra augue. Nullam id...
